PPCH News Friday, May 30, 2014 8:43:53 PM $PPCH
Post# of 377
Posted On: 05/30/2014 9:43:42 PM
PPCH News Friday, May 30, 2014 8:43:53 PM $PPCH
Propanc Makes Substantial Progress With Lead Patent Application for New Cancer Treatment in Key Global Regions
GlobeNewswire - Fri May 23, 3:00PM CDT
Propanc Health Group Corporation (OTCQB
PCH) ("Propanc" or "the Company"
an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients, today announced that it has made substantial progress in connection with their ongoing efforts to secure acceptance and approval of patent applications filed around the world.
Super Stock Profits Top Five OTC Focus List: Kirin International Holding, Inc. Frozen Food Gift Group, Gray Fox Petroleum Corp, Amarantus Bioscience Holdings, Propanc Health Group Corporation
PR Newswire - Thu May 22, 8:23AM CDT
Stocks within the OTC market continued to trade lower across the board in trading yesterday as we approach todays open for the stock market. Short term traders are looking for at least one green day to hang their hats on this week as it continues to be a stock pickers market for many investors even though there are obvious pockets of strength.
Propanc Scientific Findings Published in Peer Reviewed Cancer Journal
GlobeNewswire - Wed May 21, 9:50PM CDT
Propanc Health Group Corporation (OTCQBPCH) ("Propanc Health Group", "Propanc" or "the Company", a developmental stage healthcare company focused on new cancer treatments for patients with solid tumors, announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP", can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology.
Propanc Health Group Targets Cancer Patient Trials in 2015
GlobeNewswire - Fri May 16, 3:00PM CDT
Propanc Health Group Corporation (OTCQBPCH) ("Propanc Health Group," "Propanc" or "the Company", a developmental stage a healthcare company focused on new cancer treatments for patients with solid tumors, today announced its key strategic objectives for the development of its lead product, PRP. This Company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers.
Propanc Makes Substantial Progress With Lead Patent Application for New Cancer Treatment in Key Global Regions
GlobeNewswire - Fri May 23, 3:00PM CDT
Propanc Health Group Corporation (OTCQB
PCH) ("Propanc" or "the Company" an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients, today announced that it has made substantial progress in connection with their ongoing efforts to secure acceptance and approval of patent applications filed around the world. Super Stock Profits Top Five OTC Focus List: Kirin International Holding, Inc. Frozen Food Gift Group, Gray Fox Petroleum Corp, Amarantus Bioscience Holdings, Propanc Health Group Corporation
PR Newswire - Thu May 22, 8:23AM CDT
Stocks within the OTC market continued to trade lower across the board in trading yesterday as we approach todays open for the stock market. Short term traders are looking for at least one green day to hang their hats on this week as it continues to be a stock pickers market for many investors even though there are obvious pockets of strength.
Propanc Scientific Findings Published in Peer Reviewed Cancer Journal
GlobeNewswire - Wed May 21, 9:50PM CDT
Propanc Health Group Corporation (OTCQB
PCH) ("Propanc Health Group", "Propanc" or "the Company", a developmental stage healthcare company focused on new cancer treatments for patients with solid tumors, announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP", can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology. Propanc Health Group Targets Cancer Patient Trials in 2015
GlobeNewswire - Fri May 16, 3:00PM CDT
Propanc Health Group Corporation (OTCQB
PCH) ("Propanc Health Group," "Propanc" or "the Company", a developmental stage a healthcare company focused on new cancer treatments for patients with solid tumors, today announced its key strategic objectives for the development of its lead product, PRP. This Company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers. 
(0)
(0)